{"schema_version":"secwatch.filing_event.v1","accession":"0001846253-23-000093","form_type":"8-K","ticker":"OABI","cik":"0001846253","company_name":"OmniAb, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.719172+00:00","generated_at":"2026-06-11T19:13:40.443437+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"OmniAb Q2 2023 revenue $6.9M, net loss $14.7M; adds four partners including Merck","bullets":["Q2 revenue $6.9M (vs $7.2M YoY); net loss $14.7M ($0.15/share) vs $10.3M loss YoY.","H1 revenue $23.9M (vs $16.8M) driven by $10M milestone from TECVAYLI first commercial sale in EU.","Added 4 new partners: Merck, Neurocrine, Stanford, Seattle Children's; total active programs 305.","Batoclimab BLA accepted in China for gMG; IMVT-1402 Phase 1 initiated; GSK milestone $2.0M earned.","Cash and equivalents $103.1M; expects year-end cash slightly higher than 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001846253-23-000093","json":"https://secwatch.observer/filing/0001846253-23-000093.json","markdown":"https://secwatch.observer/filing/0001846253-23-000093.md","text":"https://secwatch.observer/filing/0001846253-23-000093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1846253/000184625323000093/0001846253-23-000093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1846253/000184625323000093/lgnd-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T19:13:40.443437+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69d73540a9535d26b9f14c450d44576bf99a9021","claim":"OmniAb, Inc. reported the three and six months ended June 30, 2023 results: revenue $6.9 million, net income $14.7 million, or $0.15 per share, EPS $0.15 per share.","evidence_excerpt":"related to our current partners as well as to securing additional partnerships,” he added. Second Quarter 2023 Financial Results Revenue for the second quarter of 2023 was $6.9 million, compared with $7.2 million for the same period in 2022. Milestone revenue was higher due to progress with the batoclimab program. Service revenue was lower primarily related to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1846253/000184625323000093/0001846253-23-000093-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Revenue","value":"$6.9 million"},{"label":"Net income","value":"$14.7 million, or $0.15 per share"},{"label":"EPS","value":"$0.15 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}